ProShare Advisors LLC Acquires 6,606 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

ProShare Advisors LLC increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 41.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 22,646 shares of the medical equipment provider’s stock after buying an additional 6,606 shares during the quarter. ProShare Advisors LLC’s holdings in Lantheus were worth $2,026,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. MPM Bioimpact LLC increased its holdings in Lantheus by 57.3% in the 4th quarter. MPM Bioimpact LLC now owns 236,213 shares of the medical equipment provider’s stock worth $21,132,000 after purchasing an additional 86,031 shares in the last quarter. Man Group plc increased its stake in shares of Lantheus by 87.0% in the fourth quarter. Man Group plc now owns 199,304 shares of the medical equipment provider’s stock valued at $17,830,000 after buying an additional 92,701 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Lantheus by 4.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,212 shares of the medical equipment provider’s stock valued at $3,508,000 after buying an additional 1,531 shares during the period. LRI Investments LLC increased its stake in shares of Lantheus by 8.4% in the fourth quarter. LRI Investments LLC now owns 3,107 shares of the medical equipment provider’s stock valued at $278,000 after buying an additional 240 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Lantheus in the fourth quarter valued at about $2,406,000. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several recent research reports. B. Riley decreased their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Finally, Truist Financial decreased their price target on Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $132.67.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by company insiders.

Lantheus Stock Down 1.8%

LNTH stock opened at $76.83 on Wednesday. Lantheus Holdings, Inc. has a twelve month low of $75.00 and a twelve month high of $126.89. The stock’s 50 day moving average is $96.20 and its 200-day moving average is $92.76. The firm has a market capitalization of $5.32 billion, a PE ratio of 12.78 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same quarter in the prior year, the business earned $1.69 EPS. The firm’s revenue for the quarter was up .8% compared to the same quarter last year. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.